Costco (NASDAQ: COST), the retailer known for bulk savings on everything from laundry detergent to gold, is now the latest destination for one of America’s most in-demand drugs: Ozempic.
In a move that could shake up how people access prescription medications, Costco has partnered with Novo Nordisk (NYSE: NVO), the manufacturer of Ozempic and Wegovy, to make these GLP-1 medications available to members at significantly reduced prices.
Costco’s New Ozempic Deal
Costco members with a valid prescription can now purchase a four-week supply of Ozempic or Wegovy for $499, roughly half the typical out-of-pocket price.
This offer is part of the Costco Member Prescription Program, and members must be enrolled to access the discounted pricing. The same $499 price point is also available through Novo Nordisk’s direct-to-consumer website and other participating retailers like CVS and Walmart.
But Costco offers a unique advantage for its premium members. Executive members who pay with the Costco Anywhere Visa® Card by Citi may be eligible for 2% Executive Member cash back plus an additional 2% Citi Visa cash back — effectively 4% total, or around $20 off a four-week supply.
That said, pharmaceutical purchases are excluded from the Executive Member 2% reward in certain states, so members should check local eligibility.
What Ozempic and Wegovy Do — And How They Differ
Both Ozempic and Wegovy contain the active ingredient semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk. These drugs work by mimicking a natural hormone that regulates blood sugar levels, slows digestion, and helps suppress appetite.
Ozempic is for diabetes, Wegovy is for weight loss, though both have found overlapping demand in the booming GLP-1 market.
Ozempic was originally approved by the FDA in 2017 for the treatment of Type 2 diabetes. It helps manage blood sugar and, as a secondary benefit, can support weight loss.
Wegovy, approved in 2021, contains the same active ingredient at a higher dose and is specifically indicated for chronic weight management in adults with obesity or overweight individuals with at least one weight-related condition.
Disclaimer: This news has been automatically collected from the source link above. Our website does not create, edit, or publish the content. All information, statements, and opinions expressed belong solely to the original publisher. We are not responsible or liable for the accuracy, reliability, or completeness of any news, nor for any statements, views, or claims made in the content. All rights remain with the respective source.